TAS::75 0849::TAS DEVELOPMENT AND MANUFACTURE OF ORAL AND TOOPICAL DOSAGE FORMS

TAS::75 0849::TAS 口服和外用剂型的开发和生产

• 批准号: 8522057
• 负责人: ROBERT GIANNINI
• 金额: $ 13万
• 依托单位: IRISYS, INC.
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-07-01 至 2015-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8522057
• 关键词: Clinical Trials; Contracts; Cream; Development; Developmental Therapeutics Program; Dosage Forms; Drug Formulations; Human; Joints; Manufactured Supplies; Mission; Ointments; Oral; Pharmacologic Substance; Pharmacology; Production; Program Development; Research Personnel; System; Tablets; Testing; Therapeutic; Therapeutic Agents; Topical application; Toxicology; cancer diagnosis; cancer therapy; capsule; novel therapeutics; programs

One of the essential parts of the mission of The Developmental Therapeutic Program (DTP) of the Division of Cancer Treatment and Diagnosis (DCTD) is involved in discovery and development of new therapeutic agents and the manufacture and supply of dosage forms to support human clinical trials under the NCI sponsorship or through investigator initiated INDs. Molecules for development enter the system under various mechanisms such as NCI Experimental Therapeutics Program (NExT) or ¿Joint Development¿ programs. The contract provides the NCI with pharmaceutical development and production of oral and topical dosage forms for use in clinical trials, advanced Pharmacology, and IND directed Toxicology testing.

癌症治疗和诊断部（DCTD）开发治疗项目（DTP）的使命之一是发现和开发新的治疗药物，并生产和供应剂型，以支持NCI赞助的或通过研究者发起的IND进行的人体临床试验。用于开发的分子在各种机制下进入系统，例如NCI实验治疗计划（NExT）或联合开发计划。该合同为NCI提供药物开发和生产口服和局部剂型，用于临床试验，高级药理学和IND指导的毒理学测试。